Advertise on podcast: Endocrine Deep Dives

Rating

★★★★★

from

2 reviews

Description

The Endocrine Deep Dive covers advanced topics in endocrinology. Utilizing AI-driven synthetic audio discussions from my own study notes, each episode breaks down complex endocrine concepts. Comprehensive Legal & Medical Disclaimer: Endocrine Deep Dives and all associated content, materials, and digital assets are produced strictly for informational and educational purposes only. The program is intended solely for healthcare providers, medical fellows, residents, and students as a supplement to their professional training. No Physician-Patient Relationship: Listening to this podcast, accessing show notes, or interacting with the platform does not establish a physician-patient, pharmacist-patient, or any other formal professional-client relationship between the host and any listener or patient. Not Medical Advice: The content does not constitute individualized medical advice, clinical diagnosis, or treatment recommendations. Patients and members of the general public must never use this content to guide personal healthcare decisions and must always consult a qualified, licensed physician or healthcare provider for any medical concerns. Clinical Responsibility: Healthcare professionals listening to this program must exercise their own independent clinical judgment. The host's interpretations, study notes, and opinions reflect personal perspectives on literature and do not set an official standard of care. Clinicians bear sole responsibility for verifying all pharmacological dosing, diagnostic criteria, and treatment protocols against official institutional guidelines, current primary literature, and individual patient presentation. Limitation of Liability: The host, creators, and associated entities disclaim any and all liability for direct, indirect, incidental, or consequential damages resulting from the use, misuse, application, or interpretation of any information presented in this podcast. Reliance on any data or opinion provided is solely at the listener's own risk.

Unlock Endocrine Deep Dives podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Endocrine Deep Dives podcast

COCPs for PMOS

2026/10/23

Combined oral contraceptives serve as first-line pharmacotherapy for non-fertility management. They suppress pituitary luteinizing hormone secretion to arrest ovarian theca-cell androgen synthesis while stimulating hepatic sex hormone-binding globulin production, drastically reducing bioactive free testosterone. This concurrent action mitigates hirsutism, restores cyclic withdrawal bleeding, and provides essential endometrial protection against unopposed estrogen-driven hyperplasia.

Mixed Meal Tolerance Test

2026/10/22

A physiological dynamic assessment evaluating beta-cell secretory capacity and postprandial glycemic regulation under mixed macronutrient stimulation. Crucial for assessing residual endogenous insulin production via C-peptide in type 1 diabetes intervention trials, evaluating post-bariatric hypoglycemia, and differentiating hyperinsulinemic hypoglycemia etiologies where standard oral glucose fails to replicate native incretin and neural secretagogue responses.

Denosumab risks in CKD

2026/10/21

Denosumab carries a marked risk of profound, refractory hypocalcemia in advanced chronic kidney disease, particularly stages 4 to 5D and comorbid CKD-mineral and bone disorder. In these patients, impaired calcitriol synthesis and secondary hyperparathyroidism render systemic calcium homeostasis acutely dependent on continuous skeletal resorption. Rapid RANK-ligand inhibition abruptly halts osteoclastic efflux, precipitating dangerous calcium nadirs typically occurring two to ten weeks post-injection. Severe cases carry documented risks of lethal arrhythmias, seizures, and exacerbation of adynamic bone disease. Clinical management mandates rigorous pre-treatment evaluation of baseline mineral metabolism, aggressive replete therapy with calcitriol and calcium salts, and frequent post-dose biochemical surveillance.

Outpatient management of DKA

2026/10/20

Outpatient management of diabetic ketoacidosis is inherently limited to early intervention during impending ketosis, as overt DKA with metabolic acidosis and volume depletion mandates emergency evaluation and inpatient intravenous resuscitation. In ambulatory patients with elevated capillary beta-hydroxybutyrate and hyperglycemia, home triage focuses on aggressive subcutaneous rapid-acting insulin administration, oral carbohydrate-electrolyte rehydration, and frequent ketone monitoring. However, persistent hyperketonemia exceeding 3.0 mmol/L, refractory nausea, vomiting, mental status alteration, or hemodynamic instability represent unequivocal failure of outpatient management requiring immediate transfer for intravenous insulin infusion, potassium repletion, and systemic acid-base correction.

MACS

2026/10/19

Mild autonomous cortisol secretion, or MACS, represents subtle hypothalamic-pituitary-adrenal axis dysregulation most frequently encountered during the workup of adrenal incidentalomas. Defined primarily by a post-one-milligram dexamethasone suppression test cortisol level exceeding 1.8 micrograms per deciliter in the absence of overt Cushingoid physical features, this biochemical state lacks classic signs but carries significant cardiometabolic morbidity. Pathophysiologically, sustained low-grade hypercortisolemia exacerbates insulin resistance, hypertension, dyslipidemia, and vertebral skeletal fragility. Clinical management hinges on individualized risk stratification: optimizing medical therapy for metabolic and bone complications while evaluating unilateral laparoscopic adrenalectomy for younger patients or those with rapidly progressing, refractory metabolic comorbidities.

Familial hyperaldosteronism type 2

2026/10/16

Familial hyperaldosteronism type 2 is an autosomal dominant form of primary aldosteronism caused predominantly by gain-of-function mutations in the CLCN2 gene, which encodes the ClC-2 voltage-gated chloride channel. These mutations lead to increased channel opening, resulting in membrane depolarization of adrenal zona glomerulosa cells, activation of calcium signaling, and autonomous overproduction of aldosterone. Unlike type 1, this condition is non-suppressible with glucocorticoids and exhibits significant phenotypic overlap with sporadic primary aldosteronism, frequently presenting with early-onset hypertension, variable hypokalemia, and a high prevalence of aldosterone-producing adenomas. Diagnostic evaluation relies on demonstrating primary aldosteronism in multiple family members after excluding glucocorticoid-remediable aldosteronism, and clinical management centers on mineralocorticoid receptor antagonists or surgical adrenalectomy when unilateral adenomas are identified.

Phosphopenic Osteomalacia

2026/10/15

Phosphopenic disorders encompass conditions characterized by systemic phosphate wasting or deficiency, driven primarily by renal tubular defects, fibroblast growth factor 23 excess, or impaired gastrointestinal absorption. Key clinical manifestations include osteomalacia, rickets, muscle weakness, and profound fatigue. Diagnostic evaluation requires rigorous assessment of serum phosphate, fractional excretion of filtered phosphate, fibroblast growth factor 23 levels, and 1,25-dihydroxyvitamin D status. Management focuses on targeted etiology-specific therapy, incorporating phosphate supplementation combined with active vitamin D analogs to restore biochemical homeostasis and skeletal integrity while avoiding hypercalciuria and nephrocalcinosis.

Calcipenic Osteomalacia

2026/10/14

Calcipenic osteomalacia presents with low-to-normal calcium, elevated PTH, hypophosphatemia, elevated alkaline phosphatase, and low urinary calcium. Evaluation requires ruling out pseudohypocalcemia and hypomagnesemia, followed by renal function assessment to distinguish renal osteodystrophy from calcipenic etiology. Paired vitamin D metabolite testing is critical: 25-hydroxyvitamin D assesses storage stores, while calcitriol identifies enzymatic defects (CYP27B1 in VDDR1A, CYP2R1 in VDDR1B) or end-organ resistance (VDDR2A). Non-responders require evaluation for malabsorption, hepatic CYP3A4 induction from antiepileptics, or isolated dietary calcium deficiency. Finally, full vitamin D repletion is necessary to unmask normocalcemic primary hyperparathyroidism, while isolated hypophosphatemia with suppressed calcitriol warrants evaluation for FGF23-mediated oncogenic osteomalacia.

Calcipenic and Phosphopenic Osteomalacia

2026/10/13

Calcipenic osteomalacia arises primarily from vitamin D deficiency or resistance, or severe calcium malabsorption, resulting in impaired mineralization due to defective intestinal calcium transport and secondary hyperparathyroidism that accelerates bone resorption and hypophosphatemia. Phosphopenic osteomalacia stems from renal phosphate wasting, frequently driven by excess fibroblast growth factor 23 or hereditary tubular defects, which directly impairs hydroxyapatite crystal formation. Both entities manifest with bone pain, proximal muscle weakness, and pseudofractures, but precise differentiation via serum calcium, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, intact parathyroid hormone, and fibroblast growth factor 23 levels is essential to direct targeted replacement or mechanism-specific antineoplastic or biological therapies.

Vitamin D Formulations

2026/10/12

Clinical management of vitamin D deficiency requires distinguishing between native secosteroids and hydroxylated metabolites based on individual metabolic clearance and organ function. Cholecalciferol maintains superior pharmacokinetics over ergocalciferol due to higher hepatic CYP2R1 affinity, stronger vitamin D-binding protein avidity, and a longer half-life, resulting in more sustained serum 25-hydroxyvitamin D elevation. In patients with severe malabsorption, hepatic dysfunction, or acute deficiency, calcifediol offers direct intestinal absorption and rapid hepatic-independent repletion. Calcitriol and active analogs bypass renal CYP27B1 1-alpha-hydroxylation, making them strictly indicated for advanced chronic kidney disease, hypoparathyroidism, or specific metabolic bone disorders rather than nutritional deficiency.

Teprotumumab

2026/10/08

Teprotumumab is a fully human monoclonal antibody targeting the insulin-like growth factor 1 receptor, revolutionizing the medical management of active thyroid eye disease. By blocking receptor signaling on orbital fibroblasts, it reduces inflammation, halts tissue expansion, and drives significant proptosis reduction and soft tissue improvement. Infused every three weeks for eight infusions, it offers an effective alternative to surgical decompression. Clinical monitoring must account for adverse effects, notably hyperglycemia and manageable hearing impairment.

Fragile X Premutation

2026/10/07

Fragile X premutation carriers harbor FMR1 allele expansions containing fifty-five to two hundred CGG repeats, predisposing them to distinct clinical syndromes driven by elevated toxic messenger ribonucleic acid levels. Adult carriers face risks of fragile X-associated tremor ataxia syndrome presenting with progressive cerebellar ataxia and intention tremor, alongside fragile X-associated primary ovarian insufficiency in women. Clinical management requires genetic counseling, family screening, and targeted neurological and endocrine surveillance.

Bone Turnover Markers

2026/10/06

PODCAST SUMMARY: Bone turnover markers provide dynamic, real-time biochemical assessment of skeletal metabolism by quantifying bone formation through serum osteocalcin and procollagen type 1 N-terminal propeptide alongside bone resorption via serum and urinary C-telopeptides. These analytes reflect rapid cellular activity months before dual-energy X-ray absorptiometry can detect significant mineral density changes, serving as essential clinical tools for monitoring antiresorptive and anabolic osteoporosis therapies, evaluating treatment adherence, and diagnosing metabolic bone disorders.

Hyperparathyroidism: Surgery vs Bisphosphonates Timing

2026/10/05

Primary hyperparathyroidism management hinges on distinguishing symptomatic from asymptomatic disease and assessing surgical candidacy according to established biochemical and densitometric thresholds. Parathyroidectomy remains the only curative intervention, durably correcting hypercalcemia, halting bone mineral density loss, and reducing nephrolithiasis risk. Bisphosphonates offer a temporary medical alternative for severe hypercalcemia or when surgery is contraindicated, but they fail to address the underlying glandular pathology or alter the natural history of parathyroid-driven bone resorption.

Persistent Post Thyroidectomy Tingling Despite Normocalcemia

2026/10/02

Post thyroidectomy hypocalcemia typically presents with perioral tingling and neuromuscular irritability driven by transient or permanent hypoparathyroidism. Early clinical identification relies on eliciting Chvostek and Trousseau signs alongside monitoring ionized calcium levels. Management strategies incorporate oral calcium supplementation and active vitamin D analogues to maintain safe serum thresholds and prevent tetany, while severe symptomatic drops mandate prompt intravenous calcium gluconate administration.